Cognitive dysfunction; Generalized fatigue; Dizziness; Headaches; Nausea; Severe itchiness entire body; Musculoskeletal pain; Temperature dysregulation; Severe skin hypersensitivity; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 17-year-old male patient received bnt162b2 (BNT162B2), on 29Apr2021 at 12:00 as dose 2, single (Lot number: EW0171) at the age of 17 years, in left arm for covid-19 immunisation. The patient's relevant medical history included: "Anxiety" (unspecified if ongoing); "ADHD" (unspecified if ongoing). There were no concomitant medications. Vaccination history included: bnt162b2 (Dose 1, single, Batch/Lot No: ER8737, Location of injection: Arm Left, At 12:00 PM), administration date: 02Apr2021, for COVID-19 immunisation. The following information was reported: COGNITIVE DISORDER (disability) with onset May2021, outcome "not recovered", described as "Cognitive dysfunction"; DIZZINESS (disability) with onset May2021, outcome "not recovered"; FATIGUE (disability) with onset May2021, outcome "not recovered", described as "Generalized fatigue"; HEADACHE (disability) with onset May2021, outcome "not recovered", described as "Headaches"; MUSCULOSKELETAL PAIN (disability) with onset May2021, outcome "not recovered"; NAUSEA (disability) with onset May2021, outcome "not recovered"; PRURITUS (disability) with onset May2021, outcome "not recovered", described as "Severe itchiness entire body"; HYPERAESTHESIA (disability) with onset May2021, outcome "not recovered", described as "Severe skin hypersensitivity"; TEMPERATURE REGULATION DISORDER (disability) with onset May2021, outcome "not recovered", described as "Temperature dysregulation". The events "cognitive dysfunction", "generalized fatigue", "dizziness", "headaches", "nausea", "severe itchiness entire body", "musculoskeletal pain", "temperature dysregulation" and "severe skin hypersensitivity" required physician office visit. Therapeutic measures were taken as a result of cognitive disorder, fatigue, dizziness, headache, nausea, pruritus, musculoskeletal pain, temperature regulation disorder, hyperaesthesia. Clinical course: Facility type vaccine was pharmacy or Drug Store. There was no other vaccine in four weeks. There was no other medications in two weeks. developed a constellation of symptoms after previous Covid vaccine and/or infection in Apr2021 pervasive to multiple systems mainly cognitive dysfunction, generalized fatigue, dizziness, headaches, nausea, severe itchiness entire body and widespread musculoskeletal pain accompanied by temperature dysregulation, severe skin hypersensitivity. Multiple failed medication trials including gabapentin, nortriptyline, pyridostigmine, duloxetine, venlafaxine, currently during a trial of low dose Naltrexone which might help pain symptoms, fatigue and itchiness. He was evaluated at the PRIVACY and PRIVACY who offered different modalities of multidisciplinary treatment. Adverse event resulted in [Doctor or other healthcare professional office/clinic visit, Disability or permanent damage]. Ongoing medications, testing. Patient had no known allergies.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300350650 same patient, different vaccine dose number/AE (LOE);